Cerus (NASDAQ:CERS) Releases Quarterly Earnings Results, Beats Estimates By $0.02 EPS

Cerus (NASDAQ:CERS) announced its quarterly earnings results on Thursday. The biotechnology company reported $0.00 earnings per share for the quarter, beating the consensus estimate of ($0.02) by $0.02, FiscalAI reports. The company had revenue of $60.24 million during the quarter, compared to analysts’ expectations of $55.12 million. Cerus had a negative return on equity of 33.77% and a negative net margin of 9.81%. Cerus updated its FY 2025 guidance to EPS.

Cerus Price Performance

Shares of NASDAQ:CERS traded down $0.04 during trading on Thursday, reaching $1.41. The stock had a trading volume of 983,070 shares, compared to its average volume of 1,318,572. The company has a debt-to-equity ratio of 1.01, a quick ratio of 1.35 and a current ratio of 2.00. The business has a fifty day moving average price of $1.46 and a 200-day moving average price of $1.38. The stock has a market cap of $270.30 million, a PE ratio of -14.10 and a beta of 1.67. Cerus has a 1-year low of $1.12 and a 1-year high of $2.24.

Hedge Funds Weigh In On Cerus

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Dynamic Technology Lab Private Ltd acquired a new position in Cerus during the first quarter worth $32,000. HUB Investment Partners LLC acquired a new position in Cerus during the second quarter worth $42,000. Captrust Financial Advisors boosted its stake in Cerus by 89.7% during the second quarter. Captrust Financial Advisors now owns 31,109 shares of the biotechnology company’s stock worth $44,000 after buying an additional 14,709 shares during the last quarter. Brevan Howard Capital Management LP boosted its stake in Cerus by 228.1% during the second quarter. Brevan Howard Capital Management LP now owns 47,823 shares of the biotechnology company’s stock worth $67,000 after buying an additional 33,249 shares during the last quarter. Finally, Cerity Partners LLC boosted its stake in Cerus by 46.3% during the second quarter. Cerity Partners LLC now owns 69,486 shares of the biotechnology company’s stock worth $98,000 after buying an additional 21,996 shares during the last quarter. Institutional investors and hedge funds own 78.37% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Cerus in a research report on Wednesday, October 8th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $4.00.

Cerus Company Profile

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.